Alveron Pharma announces termination of their OKL-1111 candidate

The Company stated that following a successful Phase I trial, subsequent data did not support progression of the molecule.

Recent Posts

Nijmegen, The Netherlands, December 6, 2024 – Alveron Pharma is pleased to announce today the closing of a €5.0 million Series Seed...

2nd October 2023 Nijmegen, The Netherlands Alveron Pharma announces that it has completed a Phase 1 clinical study for OKL-1111, a new...

20th March 2023 Nijmegen, The Netherlands Alveron Pharma announces that it has commenced a Phase 1 clinical study for OKL-1111, a new...